POZZATO, GABRIELE
 Distribuzione geografica
Continente #
NA - Nord America 14.773
EU - Europa 7.605
AS - Asia 1.646
AF - Africa 29
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 17
Totale 24.110
Nazione #
US - Stati Uniti d'America 14.700
PL - Polonia 1.760
UA - Ucraina 1.559
SE - Svezia 1.191
IT - Italia 1.029
HK - Hong Kong 585
CN - Cina 584
FI - Finlandia 477
DE - Germania 372
IE - Irlanda 277
BG - Bulgaria 274
TR - Turchia 253
GB - Regno Unito 205
FR - Francia 158
CA - Canada 70
CH - Svizzera 65
RU - Federazione Russa 62
BE - Belgio 52
IN - India 46
SG - Singapore 35
JP - Giappone 34
VN - Vietnam 33
NL - Olanda 23
AU - Australia 20
KR - Corea 20
RO - Romania 19
ES - Italia 16
PK - Pakistan 16
CZ - Repubblica Ceca 14
EU - Europa 14
IR - Iran 14
SN - Senegal 14
EG - Egitto 9
LU - Lussemburgo 8
BR - Brasile 7
PT - Portogallo 7
AT - Austria 6
IL - Israele 6
DK - Danimarca 5
GR - Grecia 5
HR - Croazia 5
PH - Filippine 5
NO - Norvegia 4
ZA - Sudafrica 4
AR - Argentina 3
BD - Bangladesh 3
CL - Cile 3
EE - Estonia 3
MX - Messico 3
SA - Arabia Saudita 3
A1 - Anonimo 2
BY - Bielorussia 2
HU - Ungheria 2
MO - Macao, regione amministrativa speciale della Cina 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
RS - Serbia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
CO - Colombia 1
EC - Ecuador 1
ID - Indonesia 1
IM - Isola di Man 1
JO - Giordania 1
KW - Kuwait 1
MA - Marocco 1
MK - Macedonia 1
SI - Slovenia 1
Totale 24.110
Città #
Woodbridge 1.961
Ann Arbor 1.821
Warsaw 1.757
Fairfield 1.530
Jacksonville 1.392
Houston 1.367
Chandler 1.253
Wilmington 875
Ashburn 865
Hong Kong 581
Seattle 570
Princeton 536
Cambridge 503
Trieste 311
Sofia 274
Dublin 273
Izmir 238
Beijing 212
Boardman 150
Dearborn 101
San Diego 96
Düsseldorf 63
Redwood City 59
Bern 56
Milan 53
Chicago 50
Brussels 45
Norwalk 40
Verona 40
Toronto 38
Buffalo 33
Phoenix 32
Dong Ket 30
Helsinki 29
Des Moines 28
Kunming 27
Sacile 27
Mestre 26
Jinan 25
Shanghai 25
Falls Church 24
Nanjing 23
Hefei 22
Grafing 21
Ottawa 21
Washington 20
Padova 19
Venezia 18
Guangzhou 17
Seoul 17
Bremen 16
Dakar 14
Fremont 13
Redmond 13
Shenyang 13
Kamiikebukuro 12
Singapore 12
Fuzhou 11
Brno 10
Columbus 10
Indiana 10
Lahore 10
Hebei 9
Mumbai 9
Munich 9
Udine 9
Zhengzhou 9
Hangzhou 8
New York 8
Timisoara 8
Tokyo 8
Dongguan 7
Horia 7
Kocaeli 7
Leawood 7
Taiyuan 7
Amsterdam 6
Antwerpen 6
Auburn Hills 6
London 6
Monfalcone 6
Rome 6
San Francisco 6
Los Angeles 5
Madrid 5
Nanchang 5
Pune 5
Surat 5
Tappahannock 5
Tel Aviv 5
Tianjin 5
Vienna 5
Augusta 4
Bologna 4
Cagliari 4
Casalecchio Di Reno 4
Centro 4
Clearwater 4
Edinburgh 4
Legnaro 4
Totale 17.969
Nome #
MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response 371
Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: Variables affecting specificity and effectiveness 367
Potential applications of nanocellulose-containing materials in the biomedical field 355
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies 340
Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. 330
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 307
Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines 300
Usefulness of core needle biopsy for the diagnosis of thyroid Burkitt's lymphoma: a case report and review of the literature 273
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival 254
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 249
Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases 245
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. 224
Serum Response Factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6 208
The role of the transcription factor E2F1 in hepatocellular carcinoma 206
Strategies to optimize siRNA delivery to hepatocellular carcinoma cells 179
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. 173
Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs 166
Translation Elongation 165
Haemochromatosis gene mutations in a clustered Italian population: evidence of high prevalence in people of Celtic ancestry. 163
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. 160
CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response 158
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. 156
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. 155
Metastatic angioimmunoblastic T-cell lymphoma started from thoracic paravertebral region: a Case report 155
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles 153
Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells 151
null 150
Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration 146
Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs 143
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 142
Introduction 142
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? 137
Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects 137
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 137
ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles ofTP53disrupted chronic lymphocytic leukaemia cells 136
Effects of E2F1-cyclinE1-E2 circuit down-regulation in hepatocellular carcinoma cells 136
Improving siRNA Bio-Distribution and Minimizing Side Effects 134
S-adenosylmethionine counteracts oral contraceptive hepatotoxicity in women 132
No evidence of Polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV 132
Blood flow changes in hepatocellular carcinomas after the administration of Thaliodomide by reperfusion kinetics during microbubble infusion: Preliminary results. 132
Hematologic problems in the Critically III 131
Aptamers as nano-targeting delivery devices or anti-cancer drugs for fighting tumours 126
Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells 126
Influence of acid-secretion blockers on gastric and hepatic alcohol dehydrogenase in rat 126
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. 125
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia 124
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 123
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials 122
HLA-G regulatory polymorphisms are associated with susceptibility to HCV infection 121
null 119
A case of burkitt-like B lymphoblastic lymphoma 119
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials 119
null 119
Randomized trial of combination therapy in relapser or non-responder HCV patients 117
A siRNA targeted against SRF reduce hepatocellular carcinoma cell proliferation, showing its potential use in the growth inhibition of this type of tumor 116
A new genotype: typical of Italy? 116
Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. 114
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 114
DEFB1 polymorphisms and salivary hBD-1 concentration in Oral Lichen Planus patients and healthy subjects 113
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199 111
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas 110
Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. 109
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 109
Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease 108
null 108
Merkel-cell polyomavirus and B-cell chronic lymphocytic leukemia 107
SiRNAs targeted against cyclin E1, cyclin E2 and E2F1 down regulate the growth of Hepatocellular Carcinoma showing their potential use in the prevention of this type of tumor 106
null 105
A siRNA targeted against SRF reduce hepatocellular carcinoma cell proliferation, showing its potential use in the growth inhibition of this type of tumor 105
Gastric and hepatic glutathione after ethanol load: the role of first-pass metabolism and effects of antisecretive drugs. 105
A randomized trial comparing different alfa-interferon at different dose and duration as therapy for chronic hepatitis C. 105
Evaluation of the contribution of the elongational factor 1 A isoforms in hepatocellular carcinoma celss growth 105
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 104
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 104
Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction. 103
Acute high-dose ethanol modulates glutathione levels to different degrees in various organs of the rat. 103
Low-grade malignant lymphoma, hepatitis C virus infection and mixed cryoglobulinemia. 101
Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. 101
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. 101
Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. 101
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 100
A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B 100
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells 100
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: relationship to the severity of liver disease and response to the alpha-interferon therapy. 99
The targeting of the elongation factor 1A by a DNA aptamer impairs the viability of hepatocarcinoma cells 99
Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia. 98
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 98
Role of E2F1-cycline1-cycline2 circuit in hepatocellular carcinoma cell proliferation and therapeutic potential of its down-regulation by siRNAs 97
Hepatic glutathione determination after ethanol administration in rat: evidence of the first-pass metabolism of ethanol. 97
HEPATIC GLUTATHIONE AFTER ETHANOL ADMINISTRATION IN RAT: EFFECTS OF CIMETIDINE AND OMEPRAZOLE. 96
Unconjugated hyperbilirubinemia in HBV carriers. Discriminant value of nicotinic acid (NA) test 96
Cirrhotic thrombocytopenia is a multifactorial condition: evidence of reduced platelet production and incresed platelet destruction 96
DEVELOPMENT OF CHLORAMBUCIL/HYDROXYCHLOROQUINE-LOADED ANTI-CD20 NANOPARTICLES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA : IN VITRO MODEL 96
LYMPHOCYTE SUBSETS IN HCV POSITIVE CHRONIC LIVER DISEASE. 95
ALCOHOL HEPATIC TOXICITY IN RAT: EVIDENCE OF THE UTILITY OF THE GASTRIC ETHANOL METABOLISM 95
Abnormal serum gamma-glutamyltranspeptidase in alcoholics: clues to its explanation 95
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC 95
Thalidomide in myelodysplastic syndromes 94
Prevalence of markers of autoimmunity and correlation with HCV genotypes and chronic liver disease in the general population of Northern Italy 94
B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinemia syndrome and hepatitis-C virus infection 93
Totale 14.333
Categoria #
all - tutte 60.073
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.073


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.550 0 0 0 0 0 0 0 0 0 245 913 392
2019/20204.670 230 179 189 747 289 622 493 606 387 287 412 229
2020/20213.794 399 195 421 541 241 424 146 353 127 437 119 391
2021/20222.722 71 235 151 344 42 156 100 139 367 304 166 647
2022/20233.443 376 378 295 454 374 646 29 263 406 36 125 61
2023/20241.629 165 132 84 98 159 154 296 503 21 17 0 0
Totale 24.692